Commercializing Living Therapies with CCRM
Join CCRM’s host, Krista Lamb, and cell and gene therapy experts to hear insider insights, information and trend forecasts for the regenerative medicine and cell and gene therapy industry. Listen and subscribe on your favourite podcast platform or check back on this page for new episodes. Reach the podcast team by emailing: email@example.com.
You get what you pay for
How will Canada’s health care system pay for cell and gene therapy cures?
Dr. Chris McCabe, CEO and Executive Director, Institute of Health Economics
Robert Woolstencroft, Senior Director and Head, Market Access and Reimbursement, Gilead Sciences Canada
Our guests tackle the complex question of how therapy developers working at the cutting edge of regenerative medicine can get reimbursed when they deliver on the promise of cures. How can patients on Prince Edward Island be guaranteed equitable access to innovative new therapies compared to patients in much larger provinces like Ontario or British Columbia? Performance-based payment models are often discussed, but are they really the solution? Despite Canada’s complex and fragmented health-care system, the challenges faced are by no means insurmountable. Join us to hear how political will and partnerships across stakeholders are prerequisites for building a health-care system that’s ready to equitably deliver these innovative new therapies to patients.
A busy intersection: Ethics and policy in cell and gene therapies
Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future.
Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University
Siofradh McMahon, Director, Clinical Translation and Regulatory Affairs, CCRM
Join guests for a discussion about the responsibilities of the regenerative medicine industry, exploring how ethics can and should be embedded into the world’s emerging regulatory frameworks for cell and gene therapies.
Are kneejerk, fear-based reactions influencing the regulatory environment? How can international compliance be ensured when some industries working on genetically modified organisms, such as agriculture, are less tightly regulated than therapeutics? Is the conversation around emerging therapies unbalanced, focusing too much on benefits and not enough on risks, encouraging patients to demand access to unproven, risky therapies? Listen to find out.
The Future’s Synthetic
Looking to the future of synthetic biology in cell and gene therapies.
Dr. George Church, Professor of Genetics, Harvard Medical School
Dr. Peter Zandstra C.M., Director and Professor, School of Biomedical Engineering, University of British Columbia
Hear from Drs. Church and Zandstra about the promise of the emerging synthetic biology field, looking to the impact developments will have on cell and gene therapies. They discuss how the regenerative medicine ecosystem needs to prepare for the arrival of transformative synthetic biology-based technologies, how equitable distribution can happen, and what those looking to commercialize these technologies will need to consider. The conversation also touches on the ethical considerations synthetic biology raises, asking how we stay on the right track en route to the future of personalized medicine.
Moving from A to B
Manufacturing and supply chain issues in cell and gene therapies.
Dr. Anthony Davies, Founder and CEO, Dark Horse Consulting
Rob Jones, Vice President, Global Bioservices, Cryoport Systems
It’s no secret that supply chain and manufacturing are crucial to the cell and gene therapy industry, but now the whole world seems to be paying attention. This sudden interest has made Anthony Davies and Rob Jones very popular at dinner parties! Join our guests and CCRM’s host, Krista Lamb, as we delve into some of the big issues related to manufacturing and supply chains. We discuss bringing down COGS, consider the merits of centralized vs. decentralized manufacturing, and contemplate how the industry can scale up to meet the demands of the future, when growth and uptake of cell and gene therapies increases.
Chaperoning innovation through the valley of death
The business of regenerative medicine and investment.
Dr. Cynthia Lavoie, President and Chief Investment Officer, CCRM Enterprises
Geoff MacKay, President and CEO, AVROBIO
Dr. Lavoie and Mr. MacKay share what brought them to regenerative medicine in the first place, why investors are bullish about the field, and which trends they have an eye on as they are looking to the future. Join our guests and CCRM’s host, Krista Lamb, as we unpack the business of regenerative medicine to understand what investors look for and how investment can help innovations through the infamous “valley of death,” where new inventions often fail en route to the clinic.
The importance of educating the public about cell and gene therapies
How can the regenerative medicine community create broader societal awareness?
Dr. Janet Rossant, President and Scientific Director, Gairdner Foundation
Dr. Phil Vanek, Chief Technology Officer, Gamma Biosciences
Drs. Rossant and Vanek discuss public awareness of cell and gene therapies, the importance of improving it, and how confusing and misleading claims made about unapproved stem cell treatments hinder our sector’s public education efforts. Join our guests and CCRM’s host, Krista Lamb, to hear why regenerative medicine is at a real tipping point, both in terms of public awareness, and technologies that will transform patients’ lives.